Promising Developments in Cullinan Management’s CLN-978 TCE for Autoimmune Diseases Drive Buy Rating
Leerink Partners analyst Andrew Berens reiterated a Buy rating on Cullinan Management (CGEM – Research Report) yesterday and set a price target ...